ACRS - Aclaris downgraded at Jefferies despite mid-stage win for eczema therapy
2024-01-10 15:09:26 ET
More on Aclaris Therapeutics
- Stocks To Watch: Nvidia, Lowe's, Deere And Best Buy Line Up To Report
- Aclaris posts topline data from mid-stage trial for eczema therapy
- Aclaris to slash 46% of workforce as it reprioritizes drug programs
- Seeking Alpha’s Quant Rating on Aclaris Therapeutics
- Historical earnings data for Aclaris Therapeutics
For further details see:
Aclaris downgraded at Jefferies despite mid-stage win for eczema therapy